Salud financiera de hoja de balance de Adaptive Biotechnologies
Salud financiera controles de criterios 5/6
Adaptive Biotechnologies tiene un patrimonio de los accionistas total de $223.6M y una deuda total de $132.7M, lo que sitúa su ratio deuda-patrimonio en 59.4%. Sus activos y pasivos totales son $558.5M y $334.9M respectivamente.
Información clave
59.4%
Ratio deuda-patrimonio
US$132.70m
Deuda
Ratio de cobertura de intereses | n/a |
Efectivo | US$243.33m |
Patrimonio | US$223.57m |
Total pasivo | US$334.93m |
Activos totales | US$558.51m |
Actualizaciones recientes sobre salud financiera
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Recent updates
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?
Nov 01Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher
Oct 05Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk
Jul 12Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($308.3M) de ADPT superan a sus pasivos a corto plazo ($87.6M).
Pasivo a largo plazo: Los activos a corto plazo de ADPT ($308.3M) superan a sus pasivos a largo plazo ($247.3M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ADPT tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de ADPT ha crecido de 0% a 59.4% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ADPT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ADPT dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 29.6% cada año